Archive for February, 2014

Bio Nano Chips and PillCams are the future of Healthcare Diagnostics

Friday, February 28th, 2014

The Programmable Bio-Nano Chip system is the future of healthcare diagnostics.

Six clinical trials have been carried out by the McDevitt Lab in Houston.  The clinical trials were carried out between 2009 to 2013  and involved testing the programmable bio-nano-chip for major diseases in the areas of cardiac heart disease, oral cancer, ovarian cancer, prostate cancer and drugs of abuse.

The programmable bio-nano-chip technology has the potential to change the practice of medicine by incorporating key advances in software, electronics and communication sectors for early detection of disease.  This new technology enables new medical diagnostics to be delivered, via high performance, accurate data at a reduced cost that will be directly submitted to the healthcare provider and patient.  

These nano bio chip sensors are capable of measuring the molecules of life that are present in complex bio-fluid samples taken from blood, urine and saliva.  This information is then reprogrammed, like software, so that new clinical applications can be created quickly and in a cost-effective manner.  Major work is now underway to swiftly move these medical micro-devices from the bench to the bedside.  The video below gives a quick overview.

The PillCam

Currently, the PillCam is being designed for those patients who are not candidates for colonoscopies, which translates to nearly 750,000 in the US alone.

The Food and Drug Administration (FDA) has just approved a digestible pill (DP) called the PillCam, designed by Given Imaging, Ltd (GIL).

GIL is an Israeli-based corporation that develops defense systems for military applications.

This concept utilizes a battery powered mini camera in the form of a pill that can take high-speed photos of the intestinal tract for an estimated 8 hours while recording information that can later be retrieved by a physician.  These pill-cams have the ability to get to areas where the standard colonoscopy doesn’t.

The standard colonoscope uses a thin, flexible tube that has a small video camera attached to the colonoscope, so the Doctor can take pictures. This looks at the colon and lower part of the small intestine. Another test called sigmoidoscopy shows only the rectum and the lower part of the colon.  However, current colonoscopy procedures do have restrictions in terms of what can be imaged, and they are quite intrusive. The PillCam is a clear advancement.  The second video below explains more.

Stem Cell Transplantation Trends in Patients Age 65 and Older

Monday, February 24th, 2014
Bone Marrow Stem Cell Transplant

Just 10 years ago, older patients were typically considered ineligible to receive a blood or bone marrow transplantation (BMT) to treat their blood cancer, but today, patients age 65 and older not only qualify for BMT therapy but are the fastest growing group of recipients.  This was reported at the American Society for Blood and Marrow Transplantation (ASBMT) annual meeting as it celebrates its 20th anniversary and reflects on how BMT therapy for the Medicare population has evolved.

Blood cancers, including leukemia, lymphoma and multiple myeloma, are most common in people age 65 and older. These patients now comprise 25% to 30% of all BMT recipients, according to the National Marrow Donor Program and the Center for International Blood & Marrow Transplant Research (CIBMTR). The percentage of older BMT recipients is significantly greater than a decade ago when patients over the age of 55 were excluded from BMT treatment due to concerns for chemotherapy toxicity.

However, reduced intensity chemotherapy, improved supportive care and Medicare changes have made it possible for patients age 65 and older to obtain BMT therapy, which can be lifesaving. There are currently more than 100,000 BMT survivors in the United States, and that number is projected to increase to 250,000 by 2020 and 500,000 by 2030 with 25% of the survivors being over the age of 60, according to a recent study published in Biology of Blood and Marrow Transplantation.

“Being able to expand the use of transplantation therapy into the age group that needs it the most is a breakthrough accomplishment for our field,” said C. Fred LeMaistre, MD, president of ASBMT.

The field of BMT began around 1970 when only a handful of medical centers around the world performed BMT. The field exploded in the 1980s and 1990s, and today, every major academic center in the world has a transplant program.

 

Source:               American Society for Blood and Marrow Transplantation
Read more here:   http://www.digitaljournal.com/pr/1753656#ixzz2uIG47MSn